International Journal of Hematology最新文献_第4页

Long-term immunity to measles and rubella after vaccination in adult allogeneic hematopoietic stem cell transplant recipients. 成人异体造血干细胞移植受者接种疫苗后对麻疹和风疹的长期免疫。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-12 DOI: 10.1007/s12185-025-04061-6

Satoshi Dohtan, Yasuyuki Nagata, Mitsuru Yamashita, Ryo Ikeda, Katsumi Koyauchi, Fumisato Takagi, Satoshi Uchiyama, Shinichiro Oka, Miwa Adachi, Kozue Mitsui, Tomonari Takemura, Takaaki Ono

{"title":"Long-term immunity to measles and rubella after vaccination in adult allogeneic hematopoietic stem cell transplant recipients.","authors":"Satoshi Dohtan, Yasuyuki Nagata, Mitsuru Yamashita, Ryo Ikeda, Katsumi Koyauchi, Fumisato Takagi, Satoshi Uchiyama, Shinichiro Oka, Miwa Adachi, Kozue Mitsui, Tomonari Takemura, Takaaki Ono","doi":"10.1007/s12185-025-04061-6","DOIUrl":"https://doi.org/10.1007/s12185-025-04061-6","url":null,"abstract":"Outbreaks of measles and rubella occasionally occur, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients face an increased risk of mortality from measles. This retrospective observational study assessed immunological responses to MR vaccination and long-term changes in antibody titers in adult allo-HSCT recipients. The measles and rubella cohorts included 36 and 33 patients, respectively, who received MR vaccination between March 2010 and December 2023. MR vaccination significantly increased IgG titers against measles from 5.48 (± 3.61) at T0 (pre-vaccination) to 14.15 (± 10.31) at T1 (1 year post-vaccination) and against rubella from 3.90 (± 2.82) at T0 to 58.93 (± 44.46) at T1 (both p < 0.001). Multivariate analyses in the measles cohort showed that lower IgG antibody titers at T0 were significantly associated with high responder status (OR 0.57, 95% CI 0.35-0.96, p = 0.029). High responders had significant mean changes in IgG antibody titers from T0 to each time point from T1 to T5 (5 years post-vaccination) for both measles and rubella. The annual decline in IgG titers was predicted to be 2.14 (p = 0.002) for measles and 3.15 (p = 0.51) for rubella in high responders. Despite high antibody titers, these levels decline over time, emphasizing the importance of regular monitoring and potential revaccination.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia. BCMA CAR-T细胞序贯胸内注射和静脉输注治疗复发/难治性原发性浆细胞白血病1例

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-10 DOI: 10.1007/s12185-025-04064-3

Wei Han, Shuyang Wang, Mingming Zhang, Shan Fu, Wenjun Wu, Houli Zhao, Ka Wai Wong, Sze Fai Yip, Jiazhen Cui, Alex H Chang, Guoqing Wei, He Huang, Yongxian Hu

引用次数: 0

Accurate tacrolimus monitoring by dual peripherally inserted central catheters in allogeneic HSCT. 异基因造血干细胞移植中双外周插入中心导管对他克莫司的准确监测。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-08 DOI: 10.1007/s12185-025-04056-3

Toshiro Sakai, Rie Shoji, Ryoji Tanaka, Kyoko Yukitaka, Ran Watanabe, Yuzufumi Sekiguchi, Ken Sato, Saori Shimoyama-Ibuki, Akari Goto, Yuichi Konuma

{"title":"Accurate tacrolimus monitoring by dual peripherally inserted central catheters in allogeneic HSCT.","authors":"Toshiro Sakai, Rie Shoji, Ryoji Tanaka, Kyoko Yukitaka, Ran Watanabe, Yuzufumi Sekiguchi, Ken Sato, Saori Shimoyama-Ibuki, Akari Goto, Yuichi Konuma","doi":"10.1007/s12185-025-04056-3","DOIUrl":"https://doi.org/10.1007/s12185-025-04056-3","url":null,"abstract":"Introduction: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) requires reliable vascular access for medication, transfusion, and blood sampling, which often involves painful venipuncture. This prospective study evaluated a novel dual peripherally inserted central venous catheter (PICC) technique to reduce venipuncture frequency in allo-HSCT recipients.Methods: The study enrolled 29 allo-HSCT recipients. Each patient received two single-lumen PICCs: Catheter A for tacrolimus infusion and Catheter B, positioned distally, for blood sampling. Tacrolimus concentrations from Catheter B and venipuncture were compared using Bland-Altman analysis. Catheter-related adverse events were also evaluated to assess safety.Results: PICC placement was successful in all patients. During 1378 catheter-days, one catheter-related bloodstream infection and one catheter occlusion occurred. Tacrolimus concentrations from PICC samples were strongly correlated with those of venipuncture samples (r = 0.93). Bland-Altman analysis showed good agreement, with a mean difference of 0.064 ng/mL, limits of agreement within ± 2.0 ng/mL, and no fixed bias.Conclusion: Dual single-lumen PICCs provide a safe and accurate method for tacrolimus monitoring in allo-HSCT, and may improve patient experience by reducing the need for painful venipuncture. Further randomized-controlled trials are needed to confirm the benefits of this approach and assess its applicability to the monitoring of other therapeutic agents.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort. BCR: abl1阴性MPN和CML的顺序发生，反之亦然：来自真实世界队列的结果。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-04 DOI: 10.1007/s12185-025-04046-5

Katrin Schweneker, Miriam Lenk, Wolfgang Kern, Claudia Haferlach, Manja Meggendorfer, Christian Pohlkamp, Torsten Haferlach

引用次数: 0

Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study. 三氧化二砷强化治疗新诊断儿童急性早幼粒细胞白血病的安全性和有效性：来自JPLSG AML-P13研究的结果

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-04 DOI: 10.1007/s12185-025-04060-7

Hiroyuki Takahashi, Shiro Tanaka, Yuki Yuza, Yuka Iijima-Yamashita, Daisuke Hasegawa, Hiroshi Moritake, Kiminori Terui, Shotaro Iwamoto, Akira Shimada, Jun Matsubayashi, Takao Deguchi, Yoshiko Hashii, Nobutaka Kiyokawa, Hayato Miyachi, Akiko M Saito, Takashi Taga, Souichi Adachi, Daisuke Tomizawa

{"title":"Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.","authors":"Hiroyuki Takahashi, Shiro Tanaka, Yuki Yuza, Yuka Iijima-Yamashita, Daisuke Hasegawa, Hiroshi Moritake, Kiminori Terui, Shotaro Iwamoto, Akira Shimada, Jun Matsubayashi, Takao Deguchi, Yoshiko Hashii, Nobutaka Kiyokawa, Hayato Miyachi, Akiko M Saito, Takashi Taga, Souichi Adachi, Daisuke Tomizawa","doi":"10.1007/s12185-025-04060-7","DOIUrl":"https://doi.org/10.1007/s12185-025-04060-7","url":null,"abstract":"Arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) has been shown to be effective in both adult and pediatric patients with acute promyelocytic leukemia (APL). Addition of ATO to conventional chemotherapy could lead to a reduction in the doses of cytotoxic agents, but the long-term safety of ATO is not fully understood, especially in children. The Japan Children's Cancer Group conducted a risk-stratified prospective study to investigate safety and efficacy of ATO in children with newly diagnosed APL by replacing all three intensification phases with ATO. The 3-year event-free survival and overall survival rates in 27 children were 96.3% (95% CI 76.5%-99.5%) and 100% (95% CI 87.2%-100%), respectively. Prolonged QTc interval or other cardiac conduction disorders of any grade were observed in 20 out of the 63 intensification cycles. The durations of leukocytopenia, neutropenia, and G-CSF treatment were significantly shorter in this study than in a previous Japanese study that used conventional cytotoxic chemotherapy. Furthermore, no cardiac, metabolic, renal, cutaneous, or neurological symptoms were reported for up to 5 years after completion of the protocol therapy. The JPLSG AML-P13 study demonstrated excellent outcomes and safety of ATO in children with APL.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation. 泊沙康唑作为异基因造血干细胞移植初级预防药物的有效性。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-03 DOI: 10.1007/s12185-025-04059-0

Yuta Hanyu, Junya Kanda, Mitsuhiro Sugimoto, Makoto Iwasaki, Mizuki Watanabe, Yasuyuki Arai, Chisaki Mizumoto, Toshio Kitawaki, Kouhei Yamashita, Takero Yamagiwa, Risa Taniguchi, Shunsaku Nakagawa, Atsushi Yonezawa, Tomohiro Terada, Akifumi Takaori-Kondo

{"title":"Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation.","authors":"Yuta Hanyu, Junya Kanda, Mitsuhiro Sugimoto, Makoto Iwasaki, Mizuki Watanabe, Yasuyuki Arai, Chisaki Mizumoto, Toshio Kitawaki, Kouhei Yamashita, Takero Yamagiwa, Risa Taniguchi, Shunsaku Nakagawa, Atsushi Yonezawa, Tomohiro Terada, Akifumi Takaori-Kondo","doi":"10.1007/s12185-025-04059-0","DOIUrl":"10.1007/s12185-025-04059-0","url":null,"abstract":"We retrospectively analyzed the effectiveness of posaconazole (tablet and infusion formulations) and its correlation with blood concentration in preventing invasive fungal infections (IFIs) in 360 patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) between 2010 and 2023. A total of 61 patients received posaconazole, 102 received micafungin, and 197 received fluconazole for primary prophylaxis. By day 100 post-transplant, the cumulative incidence of IFIs was significantly lower with posaconazole (5.0%) compared with fluconazole (14.4%) or micafungin (16.9%). Multivariate analysis showed that the risk of IFIs was significantly higher with fluconazole/micafungin than with posaconazole (hazard ratio 4.04, 95% CI 1.17-13.94, P = 0.027). This difference was most notable among patients with lymphoid malignancies (P = 0.053) and those undergoing repeat transplantation (P = 0.024). There were no significant differences in overall survival, non-relapse mortality, or mortality from IFI. Mean blood levels of posaconazole dropped to 0.57 μg/mL two weeks after allo-HSCT, coinciding with the observation of most IFIs in the posaconazole group shortly after transplant. Posaconazole appears to be more effective than fluconazole or micafungin as primary prophylaxis against IFIs in allo-HSCT recipients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo. 东京核心医院70岁及以下侵袭性ATL患者ATL治疗的结果

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-02 DOI: 10.1007/s12185-025-04057-2

Junya Makiyama, Nobuhiro Ohno, Koji Jimbo, Toyotaka Kawamata, Kazuaki Yokoyama, Takaaki Konuma, Seiko Kato, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Shigeo Fuji, Yoichi Imai, Satoshi Takahashi, Yasuhito Nannya, Arinobu Tojo, Takahiro Fukuda, Kaoru Uchimaru

{"title":"Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.","authors":"Junya Makiyama, Nobuhiro Ohno, Koji Jimbo, Toyotaka Kawamata, Kazuaki Yokoyama, Takaaki Konuma, Seiko Kato, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Shigeo Fuji, Yoichi Imai, Satoshi Takahashi, Yasuhito Nannya, Arinobu Tojo, Takahiro Fukuda, Kaoru Uchimaru","doi":"10.1007/s12185-025-04057-2","DOIUrl":"https://doi.org/10.1007/s12185-025-04057-2","url":null,"abstract":"Adult T-cell leukemia-lymphoma (ATL) is one of the most intractable peripheral T-cell neoplasms caused by human T-cell leukemia virus type I (HTLV-1) infection. Recently, the incidence of HTLV-1 infection and ATL has increased in non-endemic metropolitan areas in Japan. This retrospective study evaluated the clinical features and outcomes of patients with aggressive ATL aged 70 years or younger treated at a core hospital in Tokyo between 2004 and 2016. The median follow-up was 124.4 months for survivors. Among the 71 patients, 46 (64.8%) underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). The 3 year overall survival rate was 45.7% in allo-HSCT group versus 0% in non-allo-HSCT group. Patients who achieved complete/partial remission before allo-HSCT had a significantly better survival rate than those with stable/progressive disease (51.4% vs 27.3%). The 2 year cumulative incidence of relapse/progression and non-relapse mortality after allo-HSCT was 41.3% and 21.7%, respectively. In this study, a large percentage of patients underwent allo-HSCT and achieved favorable outcomes. As cases continue to rise in metropolitan areas, core hospitals will play a critical role in ATL treatment.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploration of the association between 91 inflammatory proteins and immune thrombocytopenia: a two-sample Mendelian randomization analysis. 探索91种炎症蛋白与免疫性血小板减少症之间的关系：两样本孟德尔随机化分析。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-04-22 DOI: 10.1007/s12185-025-03987-1

Aihua Qin, Dan Liu, Heshan Tang, Jinqi Li, Liling Qiu, Baohua Qian, Yan Zang

{"title":"Exploration of the association between 91 inflammatory proteins and immune thrombocytopenia: a two-sample Mendelian randomization analysis.","authors":"Aihua Qin, Dan Liu, Heshan Tang, Jinqi Li, Liling Qiu, Baohua Qian, Yan Zang","doi":"10.1007/s12185-025-03987-1","DOIUrl":"10.1007/s12185-025-03987-1","url":null,"abstract":"Objective: This study aimed to explore the association between 91 circulating inflammatory proteins and immune thrombocytopenia (ITP) using Mendelian randomization (MR).Methods: Data from genome-wide association studies (GWAS) on 91 inflammatory proteins were aggregated from the Olink Target platform, involving 14,824 participants. ITP data were sourced from the Integrative Epidemiology Unit OPEN GWAS project, which included 675 ITP patients and 488,749 controls. Mendelian randomization analysis was primarily conducted using inverse-variance weighting (IVW), supplemented by MR-Egger, weighted median, simple mode, and weighted mode. Pleiotropy and heterogeneity of the instrumental variables were assessed using the MR-Egger-intercept test and Cochran's Q test, with results visualized through scatter plots, funnel plots, and leave-one-out plots.Results: The IVW method indicated an association between six specific circulating inflammatory proteins and ITP. Four proteins (CCL4, CXCL9, IL-12B, and SCF) were positively associated with ITP, while two proteins (IL-1α, TRANCE) showed a negative correlation.Conclusion: The findings suggest a potential link between circulating inflammatory proteins and ITP, providing insights for future therapeutic strategies and biomarker identification.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"372-380"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM. talquetamab是一种人源化GPRC5D x CD3双特异性抗体，用于日本复发/难治性MM患者的i期研究。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-05-09 DOI: 10.1007/s12185-025-03991-5

Shinsuke Iida, Kazutaka Sunami, Shigeki Ito, Junichiro Yuda, Ei Fujikawa, Mikihiro Takamoto, Kensuke Aida, Hiroshi Yamazaki, Marimo Takahashi, Tadao Ishida

{"title":"Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM.","authors":"Shinsuke Iida, Kazutaka Sunami, Shigeki Ito, Junichiro Yuda, Ei Fujikawa, Mikihiro Takamoto, Kensuke Aida, Hiroshi Yamazaki, Marimo Takahashi, Tadao Ishida","doi":"10.1007/s12185-025-03991-5","DOIUrl":"10.1007/s12185-025-03991-5","url":null,"abstract":"The bispecific antibody talquetamab demonstrated substantial responses in heavily pretreated relapsed or refractory multiple myeloma (RRMM) in the global phase 1/2 MonumenTAL-1 study. This study, evaluated the safety and efficacy of talquetamab in Japanese patients with RRMM pretreated with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody. The primary endpoints were frequency and type of treatment-emergent adverse events (TEAEs) and serious AEs including dose-limiting toxicity (DLT). The secondary endpoints were overall response (ORR; partial response or better), duration of, and time to response. At data cutoff, 15 patients had received subcutaneous talquetamab at three doses (Cohort 1: 135 µg/kg weekly [QW, n = 4]; Cohort 2: 400 µg/kg [QW, n = 5]; Cohort 3: 800 µg/kg [Q2W, n = 6]). No DLTs, deaths, or AE-related dose reductions/treatment discontinuation were observed. Common TEAEs were neutropenia (60.0%), lymphopenia (53.3%), and CRS (46.7%). TEAEs of clinical interest (all Grade ≤ 2) were dysgeusia, skin toxicity, nail disorder, and dry mouth. With an overall median follow-up of 9.0 months, the ORR was 60.0% (95% confidence interval 32.3%, 83.7%). Talquetamab showed substantial responses in Japanese patients with RRMM, consistent with the global MonumenTAL-1 study, supporting its potential as a new standard of care for Japanese RRMM patients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"421-433"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients. 小儿造血干细胞移植受者SOS/VOD的超声评分系统。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-04-26 DOI: 10.1007/s12185-025-03995-1

Mutsumi Nishida, Shinsuke Hirabayashi, Takahito Iwai, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Tatsunori Horie, Ryosuke Sakano, Yukayo Terashita, Yuko Cho, Atsushi Manabe, Takanori Teshima

{"title":"Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients.","authors":"Mutsumi Nishida, Shinsuke Hirabayashi, Takahito Iwai, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Tatsunori Horie, Ryosuke Sakano, Yukayo Terashita, Yuko Cho, Atsushi Manabe, Takanori Teshima","doi":"10.1007/s12185-025-03995-1","DOIUrl":"10.1007/s12185-025-03995-1","url":null,"abstract":"Sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) is a serious complication following hematopoietic stem cell transplantation. It is more common in children, with an incidence of approximately 20% compared to 10% in adult patients. While the Hokkaido ultrasonography (US)-based scoring system (HokUS-10 and HokUS-6) has proven effective in diagnosing SOS/VOD in adults, its utility in children remains uncertain. This study evaluated the utility of the HokUS-10/6 scoring systems in diagnosing pediatric SOS/VOD (pSOS/VOD) in a cohort of 99 patients, including 13 diagnosed with pSOS/VOD. Hyperbilirubinemia (> 2 mg/dL) was observed in only three patients (23%), whereas transfusion-refractory thrombocytopenia, hepatomegaly, and ascites were observed in all 13 patients. When the cutoff values for HokUS-10 and HokUS-6 scores were set at 4 and 2, the respective areas under the curve were 0.977 and 0.957. The sensitivity and specificity were 100% and 80% for HokUS-10, and 77% and 97% for HokUS-6, respectively. The simplified HokUS-6 may be a practical tool for diagnosing pSOS/VOD when use of the HokUS-10 scoring system is not feasible. HokUS-10/6 is important for early detection of pSOS/VOD during regular examinations and plays a valuable role in the diagnosis of clinical pSOS/VOD.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"434-443"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0